Neurodegenerative diseases have emerged as one of the toughest and potentially most attractive frontiers in specialty drug development. Companies interested in the NDD space have the option of pursuing several strategies: disease-modifying therapies, symptom management therapies, or a hybrid approach, in which symptom-modifying drugs provide near-term revenues but also have longer-term potential for disease modification. Given the extraordinary difficulty associated with producing a successful disease-modifying new therapy, drugs aimed at treating symptoms are likely to dominate the NDD space for years. Licensors are rewarding developers with promising symptom modification programs with attractive deals.
By Andrew Friedberg, PhD, Darren Eskow, and Paul Zhang
At long last, advances in basic science are translating into the development of new treatments for an array of complex,...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
